-
Doyle and colleagues performed a retrospective study of a large cohort of patients undergoing PCI at the Mayo Clinic from 1994 to 2000, to determine the long-term outcomes of BMS, with a focus on stent thrombosis and ISR.
-
The appropriate treatment of infective endocarditis (IE), to avoid embolic stroke, is unclear. Thus, Dickerman and colleagues explored the International Collaboration on Endocarditis Prospective Cohort Study (ICE-CPS) database to define the temporal occurrence of stroke in relation to antibiotic therapy.
-
Patent Foramen Ovale (PFO) has been associated with cryptogenic stroke in young individuals, but the association is less clear in older individuals where other causes of stroke predominate.
-
Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
Three criteria identify women who would benefit from empiric antibiotics for cystitis.
-
The FDA has approved another beta-adrenergic blocker.
-
Testosterone in Older Men: Is Low Normal Too Low?, CT Pulmonary Angiography as Good as Ventilation- perfusion Scanning for Suspected Pulmonary Embolus, Vertebral Fracture Begets Vertebral Fractureand
-
The 12-lead ECG and lead II rhythm strip in the Figure were obtained from a 59-year old man several days after coronary bypass. He complained of postitional chest pain. How would you interpret his ECG given this clinical context?
-
Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
Patients with a first VTE event occurring in association with a reversible or time-limited risk factor should be treated with anticoagulants for at least three months, whereas patients with a first PE should be treated for at least six to 12 months; in fact, a case can be made for indefinite anticoagulant therapy in PE patients who have a great concern about recurrent PE and/or who are minimally concerned about the bleeding risk of anticoagulant therapy and the need for frequent determinations of the INR.
